Short-term treatment with gaboxadol improves sleep maintenance and enhances slow wave sleep in adult patients with primary insomnia


Gaboxadol is a selective extrasynaptic GABAA agonist, previously in development for the treatment of insomniac patients. To evaluate the acute efficacy and safety of gaboxadol in primary insomnia (PI). This was a randomised, double-blind, four-way crossover, polysomnograph study comparing gaboxadol 10 and 20 mg (GBX20) to placebo in 40 adults with the… (More)
DOI: 10.1007/s00213-007-0866-0


3 Figures and Tables

Slides referencing similar topics